These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 10614800)

  • 1. Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine.
    Kancherla MK; Salti HI; Mulderink TA; Parker M; Bonow RO; Mehlman DJ
    Am J Cardiol; 1999 Dec; 84(11):1335-8. PubMed ID: 10614800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine.
    Gardin JM; Schumacher D; Constantine G; Davis KD; Leung C; Reid CL
    JAMA; 2000 Apr; 283(13):1703-9. PubMed ID: 10755496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine.
    Ryan DH; Bray GA; Helmcke F; Sander G; Volaufova J; Greenway F; Subramaniam P; Glancy DL
    Obes Res; 1999 Jul; 7(4):313-22. PubMed ID: 10440587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs.
    Khan MA; Herzog CA; St Peter JV; Hartley GG; Madlon-Kay R; Dick CD; Asinger RW; Vessey JT
    N Engl J Med; 1998 Sep; 339(11):713-8. PubMed ID: 9731086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group.
    Weissman NJ; Tighe JF; Gottdiener JS; Gwynne JT
    N Engl J Med; 1998 Sep; 339(11):725-32. PubMed ID: 9731088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine.
    Gardin JM; Weissman NJ; Leung C; Panza JA; Fernicola D; Davis KD; Constantine GD; Reid CL
    JAMA; 2001 Oct 24-31; 286(16):2011-4. PubMed ID: 11667938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.
    Jick H; Vasilakis C; Weinrauch LA; Meier CR; Jick SS; Derby LE
    N Engl J Med; 1998 Sep; 339(11):719-24. PubMed ID: 9731087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities.
    Jollis JG; Landolfo CK; Kisslo J; Constantine GD; Davis KD; Ryan T
    Circulation; 2000 May; 101(17):2071-7. PubMed ID: 10790349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography.
    Mast ST; Jollis JG; Ryan T; Anstrom KJ; Crary JL
    Ann Intern Med; 2001 Feb; 134(4):261-6. PubMed ID: 11182835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs.
    Burger AJ; Charlamb MJ; Singh S; Notarianni M; Blackburn GL; Sherman HB
    Int J Cardiol; 2001 Jul; 79(2-3):159-65. PubMed ID: 11461737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study.
    Palmieri V; Arnett DK; Roman MJ; Liu JE; Bella JN; Oberman A; Kitzman DW; Hopkins PN; Morgan D; de Simone G; Devereux RB
    Am J Med; 2002 Jun; 112(9):710-5. PubMed ID: 12079711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of valvular-regurgitation associated with dexfenfluramine three to five months after discontinuation of treatment.
    Weissman NJ; Tighe JF; Gottdiener JS; Gwynne JT
    J Am Coll Cardiol; 1999 Dec; 34(7):2088-95. PubMed ID: 10588229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valvular heart disease associated with fenfluramine-phentermine.
    Connolly HM; Crary JL; McGoon MD; Hensrud DD; Edwards BS; Edwards WD; Schaff HV
    N Engl J Med; 1997 Aug; 337(9):581-8. PubMed ID: 9271479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies.
    Sachdev M; Miller WC; Ryan T; Jollis JG
    Am Heart J; 2002 Dec; 144(6):1065-73. PubMed ID: 12486432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.
    Wee CC; Phillips RS; Aurigemma G; Erban S; Kriegel G; Riley M; Douglas PS
    Ann Intern Med; 1998 Dec; 129(11 Pt 1):870-4. PubMed ID: 9867728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of selective serotonin reuptake inhibitor therapy on heart valves in patients exposed to benfluorex: a multicentre study.
    Maréchaux S; Jeu A; Jobic Y; Ederhy S; Donal E; Réant P; Abouth S; Arnasteen E; Boulanger J; Ennezat PV; Garban T; Szymanski C; Tribouilloy C
    Arch Cardiovasc Dis; 2013; 106(6-7):349-56. PubMed ID: 23876809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease.
    Lepor NE; Gross SB; Daley WL; Samuels BA; Rizzo MJ; Luko SP; Hickey A; Buchbinder NA; Naqvi TZ
    Am J Cardiol; 2000 Jul; 86(1):107-10. PubMed ID: 10867106
    [No Abstract]   [Full Text] [Related]  

  • 18. Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience.
    Teramae CY; Connolly HM; Grogan M; Miller FA
    Mayo Clin Proc; 2000 May; 75(5):456-61. PubMed ID: 10807073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heart valve lesions in patients treated with appetite suppressants.
    Pi-Sunyer FX
    Obes Res; 1999 Jul; 7(4):414-6. PubMed ID: 10440599
    [No Abstract]   [Full Text] [Related]  

  • 20. Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents.
    Volmar KE; Hutchins GM
    Arch Pathol Lab Med; 2001 Dec; 125(12):1555-61. PubMed ID: 11735689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.